# Chronic kidney disease impairs prognosis in electrical storm

Kathrin Weidner<sup>1</sup> • Michael Behnes<sup>1</sup> • Tobias Schupp<sup>1</sup> • Jorge Hoppner<sup>2</sup> • Uzair Ansari<sup>1</sup> • Julian Mueller<sup>1</sup> • Simon Lindner<sup>1</sup> • Martin Borggrefe<sup>1</sup> • Seung-hyun Kim<sup>1</sup> • Aydin Huseyinov<sup>1</sup> • Dominik Ellguth<sup>1</sup> • Muharrem Akin<sup>3</sup> • Dirk Große Meininghaus<sup>4</sup> • Thomas Bertsch<sup>5</sup> • Gabriel Taton<sup>1</sup> • Armin Bollow<sup>1</sup> • Thomas Reichelt<sup>1</sup> • Niko Engelke<sup>1</sup> • Linda Reiser<sup>1</sup> • Ibrahim Akin<sup>1</sup>

Received: 6 October 2020 / Accepted: 27 December 2020 / Published online: 23 January 2021  $\odot$  The Author(s) 2021

## Abstract

**Background** The study sought to assess the prognostic impact of chronic kidney disease (CKD) in patients with electrical storm (ES). ES represents a life-threatening heart rhythm disorder. In particular, CKD patients are at risk of suffering from ES. However, data regarding the prognostic impact of CKD on long-term mortality in ES patients is limited.

**Methods** All consecutive ES patients with an implantable cardioverter–defibrillator (ICD) were included retrospectively from 2002 to 2016. Patients with CKD (MDRD-GFR < 60 ml/min/1.73 m<sup>2</sup>) were compared to patients without CKD. The primary endpoint was all-cause mortality at 3 years. Secondary endpoints were in-hospital mortality, cardiac rehospitalization, recurrences of electrical storm (ES-R), and major adverse cardiac events (MACE) at 3 years.

**Results** A total of 70 consecutive ES patients were included. CKD was present in 43% of ES patients with a median glomerular filtration rate (GFR) of 43.3 ml/min/1.73 m<sup>2</sup>. CKD was associated with increased all-cause mortality at 3 years (63% vs. 20%; p = 0.001; HR = 4.293; 95% CI 1.874–9.836; p = 0.001) and MACE (57% vs. 30%; p = 0.025; HR = 3.597; 95% CI 1.679–7.708; p = 0.001). In contrast, first cardiac rehospitalization (43% vs. 45%; log-rank p = 0.889) and ES-R (30% vs. 20%; log-rank p = 0.334) were not affected by CKD. Even after multivariable adjustment, CKD was still associated with increased long-term mortality (HR = 2.397; 95% CI 1.012–5.697; p = 0.047), as well as with the secondary endpoint MACE (HR = 2.520; 95% CI 1.109–5.727; p = 0.027).

Conclusions In patients with ES, the presence of CKD was associated with increased long-term mortality and MACE.

Keywords Electrical storm · Chronic kidney disease · Long-term mortality · MACE

Michael Behnes michael.behnes@umm.de

- <sup>1</sup> First Department of Medicine, University Medical Centre Mannheim, Faculty of Medicine Mannheim, University of Heidelberg, Mannheim 68167, Deutschland
- <sup>2</sup> Clinic for Diagnostic and Interventional Radiology Heidelberg, University Heidelberg, Heidelberg, Germany
- <sup>3</sup> Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany
- <sup>4</sup> Department of Cardiology, Carl-Thiem-Klinikum Cottbus, Cottbus, Germany
- <sup>5</sup> Institute of Clinical Chemistry, Laboratory Medicine and Transfusion Medicine, General Hospital Nuremberg, Paracelsus Medical University, Nuremberg, Germany

# **1** Introduction

Electrical storm (ES) is defined as  $\geq 3$  distinct episodes of sustained ventricular tachycardia (VT) or fibrillation (VF) within 24 h requiring implantable cardioverter-defibrillator (ICD) therapy [1-3]. The clinical presentation of ES is heterogeneous and differs between asymptomatic patients and those with severe hemodynamic instability or cardiac death [4]. ES is still associated with increased mortality of 40% at 1 year. whereas the causative pathology remains unclear in the vast majority of patients [3, 5]. Pathophysiologically, ES represents a condition associated with increased sympathetic activity [6, 7]. Several comorbidities coexisting in ES patients, such as congestive heart failure, metabolic syndrome, and chronic kidney disease (CKD), may further increase the sympathetic tone [6, 7]. In particular, CKD is a major burden in patients with cardiovascular diseases, whereas most studies usually exclude patients with advanced stages of CKD [8, 9]. Within the last decade, it has been demonstrated that even



mild forms of CKD may be associated with cardiovascular morbidity and mortality [10]. Such patients are at increased risk of acute or chronic electrolyte alterations, autonomic imbalance, micro- and macroangiopathy, left ventricular hypertrophy or fibrosis and acquired OT prolongation. Alongside these risk factors, oxidative stress, metabolic acidosis, and hyperuremia increase the risk of ventricular tachyarrhythmias [10]. The imbalance of the autonomic nervous system, reflected by increased sympathetic activity, has been investigated within the causative context of ES [6, 11]. Consequently, a main objective in the therapy and prevention of ES represents the reduction of sympathetic activity by administration of beta-blockers. Furthermore, unnecessary ICD shocks during ES should be avoided and alternative therapeutic options such as anti-tachycardia pacing (ATP) or attenuated VT detection cluster should be applied [2, 12]. It is important to identify clinical risk factors impacting the longterm prognosis of ES patients. However, the prognostic impact of CKD in patients suffering from ES has rarely been investigated. Therefore, the present study evaluates the longterm prognostic impact of CKD in patients with ES.

## 2 Methods

## 2.1 Study population

This retrospective study included all consecutive patients presenting with ES from 2002 until 2016 at one institution. ES was defined as  $\geq$  3 episodes of ventricular tachyarrhythmias delimited by at least 5 min leading to appropriate ICD therapy during a single 24-h time period [1]. Only ICD recipients were included.

All relevant clinical data were documented using the electronic hospital information system, ICD protocols, discharge letters, daily charts, patients' files, and reports from diagnostic testing, including 12-lead electrocardiogram (ECG) and Holter ECG being assessed during clinical routine. In detail, data documentation comprised baseline characteristics, prior medical history, prior medical treatment, length of index stay, detailed findings of laboratory values at baseline, and data derived from all non-invasive or invasive cardiac diagnostics and device therapies, such as coronary angiography, electrophysiological examination, and imaging modalities, such as echocardiography or cardiac magnetic resonance imaging (cMRI). The documentation period lasted from the index event until 2016. Independent cardiologists performed documentation of all medical data at the time of the patients' individual clinical presentation period, being blinded to final data analyses. The present study is derived from a retrospective analysis of the Registry of Malignant Arrhythmias and Sudden Cardiac Death-Influence of Diagnostics and Interventions (RACE-IT) and represents a single-center registry including consecutive patients presenting with ventricular tachyarrhythmias and aborted cardiac arrest being acutely admitted to the University Medical Center Mannheim (UMM), Germany (clinicaltrials.gov identifier NCT02982473) from 2002 until 2016. The registry was carried out according to the principles of the Declaration of Helsinki and was approved by the medical ethics committee II of the Faculty of Medicine Mannheim, University of Heidelberg, Germany.

## 2.2 Risk stratification

For the present analysis, ES patients with CKD were compared to ES patients without CKD (non-CKD). Accordingly, CKD was defined as abnormalities of kidney function with health implications accompanied by a glomerular filtration rate (GFR) < 60 ml/min/1.73 m<sup>2</sup> (GFR categories G3a–G5) and a duration > 3 months [13]. All CKD patients were included according to current guidelines, irrespective of the CKD stadium [13].

#### 2.3 Definition of endpoints

The primary endpoint was long-term all-cause mortality at 3 years. Secondary endpoints comprised in-hospital mortality, first cardiac rehospitalization, major adverse cardiac event (MACE), and ES-R at long-term follow-up of 3 years. The first cardiac rehospitalization was related to recurrent VT and VF, as well as related to cardiopulmonary resuscitation (CPR), acute heart failure, or acute myocardial infarction (AMI) [14]. AMI was defined according to current guidelines as the presence of an acute myocardial injury with clinical evidence of acute myocardial ischemia and detection of a rise and/or fall of cTn values with at least one value above the 99th percentile (URL). Furthermore, at least one of the following symptoms was present: symptoms of myocardial ischemia, new ischemic ECG changes, development of pathological Q waves, imaging evidence of new loss of viable myocardium or new regional wall motion abnormality in a pattern consistent with an ischemic etiology, and identification of a coronary thrombus by angiography [14, 15]. MACE were defined as the composite of AMI, target vessel revascularization (TVR) by percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), and the primary endpoint of all-cause mortality [16]. Recurrence of electrical storm (ES-R) was defined as the recurrence of further episodes of ES at follow-up beyond the initial 24 h of prior ES [2]. The follow-up period lasted until 2016. All-cause mortality was documented using our electronic hospital information system and by directly contacting state resident registration offices (bureau of mortality statistics) across Germany. Identification of patients was verified by place of name, surname, day and place of birth, and registered living address.

#### 2.4 Statistical methods

Quantitative data are presented as mean ± standard error of mean (SEM), median and interquartile range (IQR), and ranges depending on the distribution of the data and were compared using Student's t -test for normally distributed data or the Mann-Whitney U test for non-parametric data. Deviations from a Gaussian distribution were tested by the Kolmogorov-Smirnov test. Spearman's rank correlation for non-parametric data was used to test univariate correlations. Qualitative data are presented as absolute and relative frequencies and compared using the chi-squared test or Fisher's exact test, as appropriate. The following analyses were applied stepwise to evaluate the prognostic value of predefined variables for all-cause mortality: Kaplan-Meier survival curves were calculated with log-rank testing for statistical significance. Univariable hazard ratios (HR) are given together with 95% confidence intervals. Multivariable Cox regression models with long-term mortality as the dependent variable were developed using the forward selection option, including variables of clinical prognostic relevance. The result of a statistical test was considered significant for p < 0.05, and a statistical trend was defined as p < 0.1. SAS release 9.4 (SAS Institute Inc., Cary, NC, USA) was used for statistics.

## 3 Results

## 3.1 Study population

A total of 70 patients with ES were included consecutively; 43% suffered from CKD (Table 1). The median creatinine level was 1.7 mg/dl (IQR 1-4 mg/dl) with a median GFR of 43.3 ml/min/1.73m<sup>2</sup> and a median urea level of 71 mg/dl (IQR 58–93 mg/dl, data not shown). All patients showed a moderate functional impairment of the kidney at stages 3a and 3b, according to current guidelines [13]. None of the patients showed CKD stages 4 and 5. According to this, none of the patients was on hemodialysis [13]. As shown in Table 1, most patients were males (non-CKD 93% vs. CKD 80%; p =0.122). CKD patients were older (71 vs. 65 years; p =0.047) and showed higher rates of out-of-hospital CPR (1% vs. 20%; p = 0.015). Furthermore, significantly more CKD patients had left ventricular ejection fraction (LVEF) < 35% (86% vs. 53%; p = 0.015) accompanied by significantly higher rates of ischemic cardiomyopathy (40% vs. 87%; p = 0.001). Non-CKD patients showed a trend towards numerically higher aldosterone receptor antagonist therapy than CKD patients (31% vs. 13%, p = 0.089). No differences were found in potassium levels, beta-blocker, ACE/AT1 inhibitor, amiodarone, and diuretics. No differences were found for rates of AMI and atrial fibrillation (AF). Non-CKD patients

showed a trend towards numerically higher rates of coronary angiography at index hospitalization (60% vs. 40%, p = 0.098). Accordingly, higher rates of coronary multivessel disease were found, whereas non-CKD patients showed numerically higher rates of coronary single-vessel disease or no evidence of CAD. No further differences were found regarding cardiovascular risk factors, comorbidities, electrocardiogram (ECG) data, ICD thresholds, and discharge medication (Table 1). Hemoglobin levels were significantly lower in the CKD group, reflecting the presence of renal anemia (median 12.2 vs. 14.3 g/dl).

Most ES patients had an ICD implanted for secondary prevention (62% vs. 38%). The most common ICD type was the conventional ICD (90% vs. 87%), followed by the cardiac resynchronization therapy defibrillator (CRT-D). Notably, CKD patients had numerically higher rates of CRT-D (13% vs. 5%) and no s-ICD implanted (0% vs. 5%) (Table 1).

#### 3.2 Primary endpoint all-cause mortality

All patients were followed up regarding the primary endpoint of all-cause mortality at 3 years (median 2.45 years; IQR 1.01–4.77 years). CKD patients were associated with increased rates of long-term all-cause mortality (63% vs. 20%; log-rank p = 0.001; Table 2; Fig. 1 left panel) compared with non-CKD patients. Accordingly, the risk of all-cause mortality was higher in CKD patients (HR = 4.293; 95% CI 1.874– 9.836; p = 0.001).

#### 3.3 Secondary endpoints

In contrast, in-hospital mortality rates were similar in both groups (7% vs. 0%; log-rank p = 0.180). Furthermore, rates of first cardiac rehospitalization (45% vs. 43%; log-rank p = 0.988) were similar in both groups (Table 2; Fig. 1 right panel). No differences were seen for ES-R (30% vs. 20%; p = 0.352). Additionally, increased rates of MACE were seen in CKD patients (57% vs. 30%; p = 0.025; HR 3.597; 95% CI 1.679–7.708, p = 0.001; Table 2; Fig. 2 left panel).

#### 3.4 Multivariable Cox models

In multivariable Cox regression analyses, the presence of CKD was still associated with increased long-term all-cause mortality (HR = 2.397; 95% CI 1.012–5.697; p = 0.047) besides LVEF < 35% (HR 9.015, 95% CI 1.141–71.126, p = 0.037) (Table 3). The presence of CKD was also associated with the secondary endpoint MACE (HR = 2.520; 95% CI 1.109–5.727; p = 0.027) (Table 4).

## Table 1 Baseline characteristics

Age, median (range)         65 (22-83)         71 (38-85) $0.647$ Henodialysis, $n$ (%)         37         (92)         24         (80)         0.122           Cardiopulonary resuscitation, $n$ (%)         1         (1)         6         (20) $0.015$ Dato-Ehospial         1         (1)         6         (20) $0.015$ Cardiopulonary resuscitation, $n$ (%)         Acterial hypertension         21         (53)         22         (73)         0.076           Diabetes meditas         7         (18)         9         (30)         0.228           Stanking         10         (.25)         2         (7)         (.6/4)           Cardio family history         3         (.8)         3         (10)         0.712           Cambridius, refs)         1         (.3)         3         (.10)         0.180           COPD         6         (.15)         9         (.30)         0.130           Cardiomyopathy, $n$ (%)         16         (.40)         26         (.87)         0.001           Cardiomyopathy, $n$ (%)         16         (.40)         26         (.87)         0.001           Cardiomyopathy, $n$ (%)         20 </th <th>Characteristic</th> <th colspan="2" rowspan="2">Non-CKD (<i>n</i> = 40; 57%) 65 (22–83)</th> <th colspan="2" rowspan="2">CKD (<i>n</i> = 30; 43%) 71 (38–85)</th> <th rowspan="2"><i>p</i> value 0.047</th>	Characteristic	Non-CKD ( <i>n</i> = 40; 57%) 65 (22–83)		CKD ( <i>n</i> = 30; 43%) 71 (38–85)		<i>p</i> value 0.047
Hanola logs, n (%)···(0)(0)·Male gender, n (%)37(3)24(80)0.122Cardepulnonary resuscitution, n (%)1(1)6(2)0.015Cardepulnonary resuscitution, n (%)84(13)0.420Cardiovacolar risk factors, n (%)21(53)22(73)0.076Cardiovacolar risk factors, n (%)7(18)9(30)0.258Hyperipidentia13(33)14(47)0.228Shoking0000-Cardiar family history3(8)3<(10)0.712Canonobidities, n (%)Actar mocardial infraction000Actar mocardial infraction000000COPD6(15)900.1010.001Cordiar cardiomyopathy, n (%)16(40)3(12)0.001Cardionopathy, n (%)13000.00-Coronary majography, n (%)24(60)1.0000-Coronary majography, n (%)24(60)1.0200Coronary majography, n (%)24(60)1.000-Coronary majography, n (%)24(60)1.000-Coronary majography, n (%)24(60)1.000-Coronary majography, n (%)<	Age, median (range)					
Male gander, n (%)37(93)24(80)0.122Cardiopulancary resucitation, n (%)1(1)6(20)0.015In-hospital3(8)4(7)0.405In-hospital21(53)22(73)0.076Diabetes malfitus7(18)9(30)0.238Smaking10(25)2(7)0.044Smaking10(25)2(7)0.044Cardine family hispity3(8)3(10)0.122Concerbidities, n (%)314(47)0.228Live circlusias13(3)14(47)0.228Live circlusias13(3)14(47)0.228Live circlusias13(3)14(47)0.228Live circlusias1(3)3(10)0.180Prior stoke5(13)8(27)0.01Non-ischeric cardiomyopathy, n (%)16(40)26(87)0.00/Non-ischeric cardiomyopathy16(40)26(87)0.00/Non-ischeric cardiomyopathy13(3)000.00Coronary Marce Scale3(12)2.000.000.00Short Quadditis, n (%)1(3)000.00Coronary Marce Scale3(12)2.000.000.00Coronary Marce Scale3(12)2.000.000.00Coronary Ma	Hemodialysis, <i>n</i> (%)	-	-	(0)	(0)	-
Cardiopoint Constraint Data of SolutionCardio sector (20)Constraint (20)Constraint (20)Constraint (20)Constraint (20)Constraint (20)Constraint (20)Constraint 	Male gender, $n$ (%)	37	(93)	24	(80)	0.122
Our-of-Respiral1(1)6200.01In-hospiral3(8)4(13)0.420Cardiovascular risk factors, n (%)1(53)2.2(7,00.076Dathetes mellines7(8)9(30,00.258Hyperfipidemia13(33)14(47)0.228Smoking10(25)2.(7,00.04Cardiar family history3(8)3(10)0.712Candiar family history3(33)14(47)0.228Anter mycoartial infraction13(33)14(47)0.228Laver mycoartial infraction0(0)Anter mycoarting for the factor13(33)14(47)0.228Liver erimosis1(3)3(10)0.130Prior stoka5(13)8(27)0.131Cardiomopathy, n (%)16(40)26(87)0.001Non-ischenic cardiomopathy16(40)26(87)0.001Non-ischenic cardiomopathy13(3)000.00Charactorian yandoms1(3)0(0)1.000Charactorian yandoms1(3)000.00Commary andoxade13(54)8(67)0.001Commary andoxade106 ± 0.03132 ± 0.170.0011.000Commary andoxade106 ± 0.03142 ± 0.0300.0460.030 <td>Cardiopulmonary resuscitation, n (%)</td> <td></td> <td></td> <td></td> <td></td> <td></td>	Cardiopulmonary resuscitation, n (%)					
In-hospinl38)4(13)0.420Cardiovacular isk factors, n (%)7(3)27(7)0.007Diabets mellius7(8)9(3)0.258Hyperlipidemia13(3)14(47)0.228Stonking10(25)2(7)0.044Cardia family history3(8)3(10)0.712Comobidities, n (%)13(3)14(47)0.228Liver eirhosis1(3)3(10)0.100COPD6(5)9(30)0.100Drior stroke1(3)8(27)0.131Cardiomyopathy, n (%)126(87)0.0011.000Nor-schemic archiomyopathy16(40)2601.000Nor-schemic archiomyopathy1(3)001.000Nor-schemic archiomyopathy1(3)001.000Nor-schemic archiomyopathy1(3)001.000Shard-Qi Syndrome1(3)001.000Coronary argiography, n (%)24(60)12(40)0.008Coronary argiography, n (%)2(21)000Coronary argiography, n (%)2(21)000Coronary argiography, n (%)11.040.011.0000Coronary argiography, n (%)2(21)000Coron	Out-of-hospital	1	(1)	6	(20)	0.015
Cardiovaçular isk factors, n (%)21(73)0.076Anterial hypertension7(18)9(30)0.258Hypertinjdemia13(3)14(47)0.228Smaking10(25)2(7)0.044Cardia family history3(8)3(10)0.712Controbities, n (%)Acute myocardial infraction0(0)00-Arial infralian13(3)14(47)0.228Liver cirthois1(3)30130Prior stroke5(13)827)0.131Cardioropopathy, n (%)16(40)31201000Non-ischemic cardiomyopathy4(10)31201000Non-ischemic cardiomyopathy16(3)001000Non-ischemic cardiomyopathy1(3)001000Coromy one-scale disease5(21)000Coromy one-scale disease3(21)1240)0.908Coromy one-scale disease1(25)120(3)0.445Coromy one-scale disease3(21)201000Coromy one-scale disease1(25)100(3)0.445Coromy one-scale disease3(21)2010001000Coromy one-scale disease3(21)2010001000Coromy one-s	In-hospital	3	(8)	4	(13)	0.420
Aterial hyperension21(3)22(7)0.076Diabets mollins7(18)9(30)0.238Hyperhipdenia13(33)144(47)0.238Smoking10(25)2(7)0.044Cardia family history0000-Cardia family history13(33)144(47)0.228Liver cirthosis1(3)3(10)0.180COPD6(5)9(30)0.130Prior stroke5(13)8(27)0.131Cardianyopathy. n (%)103(12)1.000Non-ischemic cardianyopathy. n (%)1(3)0(10)1.000Changedpathise, n (%)1(3)001.000Changedpathise, n (%)1(3)000.000Coronary angiography. n (%)24(60)12(40)0.098Coronary one-vased disease5(21)00.00.000Coronary one-vased disease13(54)8(67)0.001Coronary tro-vased disease13(54)8(67)0.001Coronary tro-vased disease13(54)8(67)0.001Coronary tro-vased disease13(54)8(67)0.001Coronary tro-vased disease13(54)8(67)0.001Coronary tro-vased disease13(54)8 <td>Cardiovascular risk factors, n (%)</td> <td></td> <td></td> <td></td> <td></td> <td></td>	Cardiovascular risk factors, n (%)					
Diabetes mellitus7(18)9(30)0.288Hyperinjademia13(33)14(47)0.238Snoking10(25)2(10)0.712Carnita finally history3(8)3(10)0.712Carnorbiditis, n (%)Actur any coardial infration0000-Artial fibrillation13(33)14(47)0.228Liver cirrhosis14(47)0.2281.000Diabetes cirrhosis5(13)80.1300.130Cardianyopathy, n (%)30.1310.001Non-ischenic cardianyopathy4(10)3(12)1.000Non-ischenic cardianyopathy4(10)301.000Cardianyopathy, n (%)24(50)12(0)1.000Caronary angiography, n (%)24(60)12(0)0.000Coronary angiography, n (%)10(25)10(3)0.415Coronary angiography, n (%)106 ± 0.03124.99 ± 1.210.001Caronary angiography, n (%)106 ± 0.0314 ± 3.730.001Caronary and coronary	Arterial hypertension	21	(53)	22	(73)	0.076
Hyperlipidemia13(33)14(47)0.228Smoking10(25)2(7)0.044Cardiac family history3(8)3(10)0.712Comorbidities, n (%)(3)14(47)0.228Liver cirrhosis13(3)14(47)0.228Liver cirrhosis1(3)3(10)0.180COPD6(15)9(30)0.101Drior stoke5(13)8(27)0.131Cardiamyopathy, n (%)16(10)26(87)0.001Non-ischenic cardiomyopathy4(10)26(87)0.001Non-ischenic cardiomyopathy1(3)0(1)0.001Non-ischenic cardiomyopathy1(3)0(0)1.000Short-QT syndrome1(3)0(0)1.000Lingada syndrome1(3)0(0)0Coronary ang/ensel disease5(21)0(0)0.009Coronary one-vesel disease5(21)0(0)0.001Coronary to-vesel disease13(54)8(67)1.001Coronary to-vesel disease13(54)8(67)1.001Coronary to-vesel disease13(54)8(67)1.001Coronary to-vesel disease13(54)8(67)1.001Coronary to-vesel disease13(54)8(67)	Diabetes mellitus	7	(18)	9	(30)	0.258
Smoking10(25)2(7)0.044Cardia finily history3(8)3(10)0.712Cardia finily history3(0)00-Atrial finilation13(3)14(47)0.228Atrial finilation13(3)14(47)0.238Corp Constraints1(3)3(10)0.180COPD6(15)9(30)0.130Prior stoke5(13)8(27)0.001Non-ischemic cardiomyopathy16(40)3(12)1.000Non-ischemic cardiomyopathy4(10)3(12)1.000Non-ischemic cardiomyopathy16(40)300.001Non-ischemic cardiomyopathy1(3)0(0).0001Conserva gradiography, n (%)1(3)0(0).0001Long-QT syndrome1(3)0(0).0001Coronary one-vessel disease5(21)0(0).0001Coronary three-vessel disease13(54)8(67)UEElectrophysiological examination, n (%)18.4 0.31.2 4.04.0007.0007Tabasinu (mmol/)1.3 8 ± 0.31.2 4.041.0001.0001.0001Creative protein (mg/d)1.3 8 ± 0.31.2 4.04.0007.0007Potassinu (mmol/)1.3 8 ± 0.31.2 4.04.0007.0007Creative protein (mg/d)1.3 8	Hyperlipidemia	13	(33)	14	(47)	0.228
Cardiac family history3(8)3(10)0.712Conorbidities, n (%)0000-Atrial fibrillation13(33)14(47)0.228Liver circlosis1(3)3(10)0.180Prior stroke1(3)8(27)0.131CODD6(15)9(80)0.001Diror stroke5(13)8(27)0.013Cardiomyopathy, n (%)16(40)26(87)0.001Non-ischemic cardiomyopathy4(10)3(12)1.000Not decumented20(50)1(1)0.001Chamelopathies, n (%)1(3)0(0)1.000Long CJ syndrom1(3)0(0)0.00Coronary one-vessel disease5(21)0(0)0.00Coronary one-vessel disease5(21)0(0)0.00Coronary one-vessel disease13(54)8(67)1.000Labortory data (mean ±SEM)11.06 ± 0.031.49 ± 0.070.001Creative protein (mg/d)1.06 ± 0.031.49 ± 0.010.0010.000Passian (monb1)0.06 ± 0.531.49 ± 0.010.001Creative protein (mg/d)1.51 ± 3.90.42 ± 0.10.001Passian (monb1)0.64 ± 0.531.49 ± 0.010.001Creative protein (mg/d)1.51 ± 3.90.0010.002Passian (monb1)<	Smoking	10	(25)	2	(7)	0.044
Conorbidities, n (%)       0       0       0       0       0       0         Acute myocardial infraction       13       33       14       (47)       0.228         Liver cirrhosis       1       (3)       3       (10)       0.130         COPD       6       (15)       9       (30)       0.130         Drio stroke       5       (13)       8       (27)       0.131         Cardiomyopathy, n (%)       1       (10)       3       (12)       1.000         Non-ischemic cardiomyopathy       4       (10)       3       (12)       0.000         Chamchopathiss, n (%)       1       (3)       0       (0)       1.000         Congary syndrome       1       (3)       0       (0)       0.000         Short-QT syndrome       1       (3)       0       (0)       0.000         Coronary angiography, n (%)       24       (60)       12       (40)       0.98         Coronary angiography, n (%)       10       25       10       0.31       0.445         Coronary angiography, n (%)       10       25       10       0.01       0.001         Coronary angiography, n (%)       10       23	Cardiac family history	3	(8)	3	(10)	0.712
Acute myocardial infarction00000.Atrial Bribllation13(3)14(47)0.228Liver cirrhosis1(3)3(10)0.180COPD6(15)9(30)0.131Prior stroke5(13)8(27)0.131Cardiomyopathy (%)16(40)26(87)0.001Non-ischemic cardiomyopathy4(10)3(12)1.000Not decumented20(50)1(1)0.001Chamelopathise, n(%)1(3)0(0)1.000Log 2f syndrome1(3)0(0)1.000Short-QT syndrome0(0)00-Coronary angiography, n(%)24(60)12(40)0.098Coronary non-vessel disease13(54)8(67)Coronary non-vessel disease13(54)8(67)Electrophysiological examination, n(%)10(25)10(3)0.445VT ablaio9(23)8(27)0.601GRS (MLmini) 1.73 m <sup>2</sup> )60.64.0531.49 ± 0.0070.0010.300Creating (ng(d))13.8 ± 0.31.49 ± 0.010.3000.300Creating (ng(d))13.8 ± 0.31.49 ± 0.010.3000.300Creating (ng(d))13.8 ± 0.31.42 ± 0.10.300Creating (ng(d))13.8 ± 0.31.49 ± 0.010.503Toponin (ng(d)) </td <td>Comorbidities, <math>n</math> (%)</td> <td></td> <td></td> <td></td> <td></td> <td></td>	Comorbidities, $n$ (%)					
Atrial fibrillation13(33)14(47)0.228Live circhosis1(3)3(10)0.180COPD6(15)9(30)0.130Prior stroke5(13)8(27)0.131Cardionyopathy, n (%)8(20)0.001Non-schemic cardionyopathy4(10)3(12)1.000Non-schemic cardionyopathy4(10)3(10)0.001Non-schemic cardionyopathy1(3)0(0)1.000Langada syndrome1(3)0(0)1.000Long-QT syndrome0(0)000Coronary non-vessel disease5(21)0(0)0.09Coronary non-vessel disease13(54)8(67)1.000Coronary non-vessel disease13(54)8(67)1.000Coronary non-vessel disease1.06 ± 0.0031.49 ± 0.070.0010.001Cardinu (mgd)1.06 ± 0.0331.49 ± 0.070.0010.001Creatinic (mgd)1.06 ± 0.0331.49 ± 0.070.0001Creating the proton (mgd)1.38 ± 0.31.49 ± 0.070.001Creating the proton (mgd)1.38 ± 0.31.49 ± 0.070	Acute myocardial infarction	0	(0)	0	(0)	-
Liver cirrhosis 1 (3) 3 (10) 0.180 COPD 6 (15) 9 (30) 0.130 Prior stroke 5 (13) 8 (27) 0.131 Cardiomyopathy (%) Ischemic cardiomyopathy 16 (40) 26 (87) 0.001 Non-ischemic cardiomyopathy 4 (10) 3 (12) 1.000 Not documented 20 (50) 1 (1) 0.001 Channelopathis, n (%) Brugada syndrome 1 (3) 0 (0) 1.000 Long-QT syndrome 0 (0) 0 (0) - Coronary angiography, n (%) 24 (60) 12 (40) 0.098 Coronary nor-vessel disease 5 (21) 0 (0) 0.000 Coronary nor-vessel disease 5 (21) 0 (0) 0.000 Coronary nor-vessel disease 5 (21) 0 (0) 0.000 Coronary nor-vessel disease 3 (12) 2 (17) Coronary three-vessel disease 13 (54) 8 (67) Electrophysiological examination, n (%) 10 (25) 10 (33) 0.445 VT ablation 9 (23) 8 (27) 0.637 Laboratoy data (mean ±SEM) Creatin (mg/dl) 1.54 ± 0.003 + 1.49 ± 0.07 + 0.001 Henoglobin (g/dl) 1.54 ± 0.03 + 1.49 ± 0.07 + 0.001 Potassium (mmol/l) 4.0 ± 0.1 + 4.2 ± 0.1 + 0.001 Potassium (mmol/l) 1.51 ± 3.9 + 49.9 ± 12.1 + 0.001 Potassium (mmol/l) 1.51 ± 3.9 + 49.9 ± 12.1 + 0.001 Potassium (mmol/l) 1.51 ± 3.9 + 49.9 ± 12.1 + 0.001 Potassium (mmol/l) 1.51 ± 3.9 + 49.9 ± 12.1 + 0.001 Potassium (mmol/l) 1.51 ± 3.9 + 49.9 ± 12.1 + 0.001 Potassium (mmol/l) 1.51 ± 3.9 + 49.9 ± 12.1 + 0.001 Potassium (mmol/l) 1.51 ± 3.9 + 49.9 ± 12.1 + 0.001 Potassium (mmol/l) 1.51 ± 3.9 + 49.9 ± 12.1 + 0.001 Potassium (mmol/l) 1.51 ± 3.9 + 49.9 ± 12.1 + 0.003 Toponin 1 (µg/l) 1.51 ± 3.9 + 49.9 ± 12.1 + 0.003 Potassium (mmol/l) 1.51 ± 3.9 + 49.9 ± 12.1 + 0.003 Potassium (mmol/l) 1.51 ± 3.9 + 49.9 ± 12.1 + 0.003 Potassium (mmol/l) 1.51 ± 3.9 + 40.9 ± 12.1 + 0.003 Potassium (mmol/l) 1.51 ± 3.9 + 40.9 ± 12.1 + 0.003 Potassium (mmol/l) 1.51 ± 3.9 + 40.9 ± 12.1 + 0.003 Potassium (mmol/l) 1.51 ± 3.9 + 40.9 ± 12.1 + 0.003 Potassium (mmol/l) 1.51 ± 3.9 + 40.9 ± 12.1 + 0.003 Potassium (mmol/l) 1.51 ± 3.9 + 40.9 ± 12.1 + 0.003 Potassium (mmol/l) 1.51 ± 3.9 + 40.9 ± 12.1 + 0.003 Potassium (mmol/l) 1.51 ± 3.9 + 1.4 + 1.00 + 0.003 + 0.003 Potassium (mmol/l) 1.51 ± 3.9 + 0.00 + 0.003 + 0.00 + 0.003 Potassium (mmol/l	Atrial fibrillation	13	(33)	14	(47)	0.228
COPD         6         (15)         9         (30)         0.130           Prior stoke         5         (13)         8         (27)         0.131           Cardiomyopathy         16         (40)         26         (87)         0.001           Non-ischemic cardiomyopathy         4         (10)         3         (12)         1.000           Non-ischemic cardiomyopathy         4         (10)         3         (10)         0.001           Channelopathies, $n$ (%)         Burgada syndrome         1         (3)         0         (0)         1.000           Shord-Orne         1         (3)         0         (0)         -0.00           Coronary one-vessel disease         5         (21)         0         (0)         0.00           Coronary one-vessel disease         5         (21)         0         (0)         0.00           Coronary one-vessel disease         3         (12)         2         (17)         Coronary one-vessel disease         3         (12)         0.001           Coronary one-vessel disease         3         (12)         2         (17)         Coronary one-vessel disease         3         (12)         0.001           Coronary ine-vessel disease	Liver cirrhosis	1	(3)	3	(10)	0.180
Prior stroke         5         (13)         8         (27)         0.131           Cardiomyopathy, $n$ (%)                  0.001          0.001         Not oscientic cardiomyopathy         4         (10)         3         (12)         1.000         Not documented         20         (50)         1         (1)         0.001         Chancelopathiss, $n$ (%)            Not documented         0         0         (0)         1.000         Documenta         1.000         Documenta         1.000         Documenta         1.000         Documenta         Documenta         1.000         Documenta         Documenta <td>COPD</td> <td>6</td> <td>(15)</td> <td>9</td> <td>(30)</td> <td>0.130</td>	COPD	6	(15)	9	(30)	0.130
Cardiomyopathy, $n$ (%)       16       (40)       26       (87)       0.001         Non-ischemic cardiomyopathy       4       (10)       3       (12)       1.000         Non-ischemic cardiomyopathy       4       (10)       3       (12)       1.000         Non-ischemic cardiomyopathy       4       (10)       3       (12)       1.000         Non-ischemic cardiomyopathy, $n$ (%)       0       (50)       1       (1)       0.001         Chamelopathies, $n$ (%)       1       (3)       0       (0)       1.000         Lang-QT syndrome       1       (3)       0       (0)       -         Coronary nor-vessel disease       5       (21)       0       (0)       0.005         Coronary nor-vessel disease       3       (12)       2       (17)       Coronary nor-vessel disease       3       (12)       2       (17)       Coronary thev-vessel disease       13       (54)       8       (67)       Electrophysiological examination, $n$ (%)       10       (23)       8       (27)       0.687         Laboratory data (mean ±SEM)       1.49 ± 0.007       1.49 ± 0.007       0.001       GFR (m/min/1.73 m²)       60.6 ± 0.53       1.49 ± 0.01       0.001       0.001	Prior stroke	5	(13)	8	(27)	0.131
Ischemic cardiomyopathy       16       (40)       26       (87)       0.001         Non-ischemic cardiomyopathy       4       (10)       3       (12)       1.000         Non-ischemic cardiomyopathy       20       (50)       1       (1)       0.001         Not documented       20       (50)       1       (1)       0.001         Channelopathies, $n$ (%)       3       0       (0)       1.000         Long-OT syndrome       1       (3)       0       (0)       1.000         Short-OT syndrome       0       (0)       0       (0)       -       Coronary angiography, $n$ (%)       24       (60)       12       (40)       0.098       Coronary one-vessel disease       5       (21)       0       (0)       0.405       Coronary one-vessel disease       3       (12)       2       (17)       Coronary one-vessel disease       13       (54)       8       (67)       Electrophysiological examination, $n$ (%)       10       (25)       10       (33)       0.445         VT ablation       9       (23)       8       (27)       0.687       Laboratory data (mean ±SEM)       Creatine (mg/d)       1.38 ± 0.3       1.49 ± 0.007       0.001       Reamin/1.73 m <sup>3</sup> )       60.6 ± 0.03	Cardiomyopathy, $n$ (%)					
Non-ischemic cardiomyopathy       4       (10)       3       (12)       1.000         Not documented       20       (50)       1       (1)       0.001         Channelopathies, $n$ (%)       Brugada syndrome       1       (3)       0       (0)       1.000         Dang-QT syndrome       1       (3)       0       (0)       1.000         Short-QT syndrome       0       (0)       0       (0)       -         Coronary von-vessel disease       5       (21)       0       (0)       0.002         Coronary von-vessel disease       3       (12)       2       (17)       -         Coronary von-vessel disease       13       (54)       8       (67)       -         Coronary von-vessel disease       13       (54)       8       (67)       -       -         Coronary von-vessel disease       13       (54)       8       (67)       - <td< td=""><td>Ischemic cardiomyopathy</td><td>16</td><td>(40)</td><td>26</td><td>(87)</td><td>0.001</td></td<>	Ischemic cardiomyopathy	16	(40)	26	(87)	0.001
Not documented       20       (50)       1       (1)       0.001         Channelopathies, $n$ (%)       Brugada syndrome       1       (3)       0       (0)       1.0000         Long-QT syndrome       1       (3)       0       (0)       1.0000         Short-QT syndrome       0       (0)       0       (0)       -         Coronary angiography, $n$ (%)       24       (60)       12       (40)       0.998         Coronary two-vessel disease       5       (21)       0       (0)       0.405         Coronary thre-vessel disease       13       (54)       8       (67)         Electrophysiological examination, $n$ (%)       10       (25)       10       (33)       0.445         VT ablation       9       (23)       8       (27)       0.687         Laboratory data (mean ±SEM)       1.49 ± 0.007       0.001       GFR (ml/min/1.73 m <sup>2</sup> )       60.6 ± 0.53       43 ± 3.73       0.001         GFR (ml/min/1.73 m <sup>2</sup> )       60.6 ± 0.53       42 ± 0.1       0.003       0.003         Troponin 1 (µg/1)       0.3 ± 0.1       0.4 ± 0.1       0.549       Medication at discharge, $n$ (%)         Beta-blocker       38       (95)       30       (10	Non-ischemic cardiomyopathy	4	(10)	3	(12)	1.000
Channelopathies, $n$ (%)       Image of the syndrome       Image of the	Not documented	20	(50)	1	(1)	0.001
Bragada syndrome1(3)0(0)1.000Long-QT syndrome1(3)0(0)1.000Short-QT syndrome0(0)0(0)-Coronary angiography, $n$ (%)24(60)12(40)0.098Coronary one-vessel disease5(21)0(0)0.405Coronary thre-vessel disease3(12)2(17)-Coronary thre-vessel disease13(54)8(67)-Electrophysiological examination, $n$ (%)10(25)10(33)0.445VT ablation9(23)8(27)0.667Laboratory data (mean ±SEM)-1.49 ± 0.0070.001GFR (ml/min/1.73 m <sup>2</sup> )60.6 ± 0.531.49 ± 0.0070.001GFR (ml/min/1.73 m <sup>2</sup> )60.6 ± 0.531.49 ± 0.14.2 ± 0.10.001Potasium (mmol/l)4.0 ± 0.14.2 ± 0.10.0030.001C-reactive protein (mg/dl)15.1 ± 3.949.9 ± 12.10.003C-reactive protein (mg/dl)0.3 ± 0.10.2 ± 0.40.001Medication at discharge, $n$ (%)0.533.0(100)0.230ACE inhibitor/ARB34(85)21(75)0.302Statin23(58)14(50)0.541Amiodarone24(60)18(64)0.720Aldosterone receptor antagonist12(31)4(13)0.089Diuretics23(59) <td>Channelopathies, <math>n</math> (%)</td> <td></td> <td></td> <td></td> <td></td> <td></td>	Channelopathies, $n$ (%)					
Long-QT syndrome       1       (3)       0       (0)       1.000         Short-QT syndrome       0       (0)       0       (0)       -         Coronary angiography, $n$ (%)       24       (60)       12       (40)       0.098         Coronary one-vessel disease       5       (21)       0       (0)       0.405         Coronary two-vessel disease       3       (12)       2       (17)       2         Coronary two-vessel disease       13       (54)       8       (67)       6         Electrophysiological examination, $n$ (%)       10       (25)       10       (33)       0.445         VT ablation       9       (23)       8       (27)       0.687         Laboratory data (mean ±SEM)       1.06 ± 0.003       1.49 ± 0.007       0.001         GFR (ml/min/1.73 m <sup>2</sup> )       60.6 ± 0.53       43 ± 3.73       0.001         Hemoglobin (g/dl)       13.8 ± 0.3       12.2 ± 0.4       0.001         Potassium (mon/l)       4.0 ± 0.1       4.2 ± 0.1       0.300         C-reactive protein (mg/dl)       15.1 ± 3.9       49.9 ± 12.1       0.003         Toponin I (µg/l)       0.3 ± 0.1       0.4 ± 0.1       0.541         Medication at dis	Brugada syndrome	1	(3)	0	(0)	1.000
Dot         O	Long-OT syndrome	1	(3)	0	(0)	1.000
Coronary angiography, $n$ (%)       24       (60)       12       (40)       0.098         Coronary one-vessel disease       5       (21)       0       (0)       0.405         Coronary two-vessel disease       3       (12)       2       (17)         Coronary three-vessel disease       13       (54)       8       (67)         Electrophysiological examination, $n$ (%)       10       (25)       10       (33)       0.445         VT ablation       9       (23)       8       (27)       0.687         Laboratory data (mean ±SEM)       1.06 ± 0.003       1.49 ± 0.007       0.001         GFR (ml/min/1.73 m <sup>2</sup> )       60.6 ± 0.53       43 ± 3.73       0.001         Hemoglobin (g/dl)       13.8 ± 0.3       12.2 ± 0.4       0.001         Potassium (mmol/l)       4.0 ± 0.1       4.2 ± 0.1       0.300         Creactive protein (mg/dl)       15.1 ± 3.9       49.9 ± 12.1       0.003         Toponin 1 (µg/l)       0.3 ± 0.1       0.4 ± 0.1       0.549         Medication at discharge, $n$ (%)       8       (95)       30       (100)       0.230         Statin       23       (58)       14       (50)       0.541         Amiodarone       24 <td>Short-OT syndrome</td> <td>0</td> <td>(0)</td> <td>0</td> <td>(0)</td> <td>-</td>	Short-OT syndrome	0	(0)	0	(0)	-
Coronary one-vessel disease       5       (2)       0       (0)       0.405         Coronary two-vessel disease       3       (12)       2       (17)         Coronary three-vessel disease       13       (54)       8       (67)         Electrophysiological examination, $n$ (%)       10       (25)       10       (33)       0.445         VT ablation       9       (23)       8       (27)       0.687         Laboratory data (mean ±SEM)       C       1.49 ± 0.007       0.001         GFR (ml/min/1.73 m <sup>2</sup> )       60.6 ± 0.53       43 ± 3.73       0.001         Hemoglobin (g/dl)       13.8 ± 0.3       12.2 ± 0.4       0.001         Potassium (mmol/l)       4.0 ± 0.1       4.2 ± 0.1       0.300         C-reactive protein (mg/dl)       15.1 ± 3.9       49.9 ± 12.1       0.003         Toponin I (µg/l)       0.3 ± 0.1       0.4 ± 0.1       0.549         Medication at discharge, $n$ (%)       Beta-blocker       38       (95)       30       (100)       0.230         Statin       23       (58)       14       (50)       0.541         Amiodarone       24       (60)       18       (64)       0.720         Aldosterone receptor antagonist </td <td>Coronary angiography, <math>n</math> (%)</td> <td>24</td> <td>(60)</td> <td>12</td> <td>(40)</td> <td>0.098</td>	Coronary angiography, $n$ (%)	24	(60)	12	(40)	0.098
Coronary two-vessel disease       3       (12)       2       (17)         Coronary three-vessel disease       13       (54)       8       (67)         Electrophysiological examination, $n$ (%)       10       (25)       10       (33)       0.445         VT ablation       9       (23)       8       (27)       0.687         Laboratory data (mean ±SEM)       1.06 ± 0.003       1.49 ± 0.007       0.001         GFR (ml/min/1.73 m <sup>2</sup> )       60.6 ± 0.53       43 ± 3.73       0.001         Hemoglobin (g/dl)       13.8 ± 0.3       12.2 ± 0.4       0.001         Potassium (mol/l)       4.0 ± 0.1       4.2 ± 0.1       0.300         Creactive protein (mg/dl)       15.1 ± 3.9       49.9 ± 12.1       0.003         Troponin 1 (µg/l)       0.3 ± 0.1       0.4 ± 0.1       0.549         Medication at discharge, $n$ (%)       14       (50)       0.541         Armiodarone       23       (58)       14       (50)       0.541         Amiodarone       24       (60)       18       (64)       0.720         Aldosterone receptor antagonist       12       (31)       4       (13)       0.089         Diuretics       23       (59)       20       <	Coronary one-vessel disease	5	(21)	0	(0)	0.405
Coronary three-vessel disease         13         (54)         8         (67)           Electrophysiological examination, $n$ (%)         10         (25)         10         (33)         0.445           VT ablation         9         (23)         8         (27)         0.687           Laboratory data (mean $\pm$ SEM)         1.49 $\pm$ 0.007         0.001         0.001           GFR (ml/min/1.73 m <sup>2</sup> )         60.6 $\pm$ 0.53         43 $\pm$ 3.73         0.001           Hemoglobin (g/dl)         13.8 $\pm$ 0.3         12.2 $\pm$ 0.4         0.001           Potassium (mmol/l)         4.0 $\pm$ 0.1         4.2 $\pm$ 0.1         0.300           Creactive protein (mg/dl)         15.1 $\pm$ 3.9         49.9 $\pm$ 12.1         0.003           Toponin I (µg/l)         0.3 $\pm$ 0.1         0.4 $\pm$ 0.1         0.54           Medication at discharge, $n$ (%)         14         50)         0.541           Amiodarone         24         (60)         18         (64)         0.720           Aldosterone receptor antagonist         12         (31)         4         (13)         0.089           Diuretics         23         (59)         20         (67)         0.513           ECG data (mean $\pm$ SEM)         226 $\pm$ 16         204 $\pm$ 15 <td>Coronary two-vessel disease</td> <td>3</td> <td>(12)</td> <td>2</td> <td>(17)</td> <td></td>	Coronary two-vessel disease	3	(12)	2	(17)	
Electrophysiological examination, $n$ (%)       10       (25)       10       (33)       0.445         VT ablation       9       (23)       8       (27)       0.687         Laboratory data (mean ±SEM)       1.06 ± 0.003       1.49 ± 0.007       0.001         GFR (ml/min/1.73 m <sup>2</sup> ) $60.6 \pm 0.53$ $43 \pm 3.73$ 0.001         Hemoglobin (g/dl)       13.8 ± 0.3 $12.2 \pm 0.4$ 0.001         Potassium (mmol/l) $4.0 \pm 0.1$ $4.2 \pm 0.1$ 0.300         C-reactive protein (mg/dl)       15.1 ± 3.9 $49.9 \pm 12.1$ 0.003         Troponin I (µg/l) $0.3 \pm 0.1$ $0.4 \pm 0.1$ 0.549         Medication at discharge, $n$ (%) $21$ (75)       0.302         Statin       23       (58)       14       (50)       0.541         Amiodarone       24       (60)       18       (64)       0.720         Aldosterone receptor antagonist       12       (31)       4       (13)       0.089         Diuretics       23       (59)       20       (67)       0.513       0.513         ECG data (mean ± SEM) $226 \pm 16$ $204 \pm 15$ 0.376       0.376	Coronary three-vessel disease	13	(54)	8	(67)	
VT ablation       9       (23)       8       (27)       0.687         Laboratory data (mean $\pm$ SEM)       1.49 $\pm$ 0.007       0.001         GFR (ml/min/1.73 m²) $60.6 \pm 0.53$ $43 \pm 3.73$ 0.001         Hemoglobin (g/dl) $13.8 \pm 0.3$ $12.2 \pm 0.4$ 0.001         Potassium (mmol/l) $4.0 \pm 0.1$ $4.2 \pm 0.1$ 0.003         Creactive protein (mg/dl) $15.1 \pm 3.9$ $49.9 \pm 12.1$ 0.003         Troponin I (µg/l) $0.3 \pm 0.1$ $0.4 \pm 0.1$ 0.549         Medication at discharge, n (%) $34.4$ (85) $21.4$ (75)       0.302         Statin $23$ $58$ $14.4$ (50)       0.541         Amiodarone $24$ (60) $18.4$ (64)       0.720         Aldosterone receptor antagonist $12$ $(31)$ $4$ $(13)$ 0.893         Diuretics $226 \pm 16$ $204 \pm 15$ $204 \pm 15$ $0.376$ QRS $128 \pm 21$ $127 \pm 16$ $0.957$ OT $450 \pm 18$ $423 \pm 23$ $0.378$	Electrophysiological examination, $n$ (%)	10	(25)	10	(33)	0.445
Laboratory data (mean $\pm$ SEM)       1.06 $\pm$ 0.003       1.49 $\pm$ 0.007       0.001         GFR (ml/min/1.73 m <sup>2</sup> )       60.6 $\pm$ 0.53       43 $\pm$ 3.73       0.001         Hemoglobin (g/dl)       13.8 $\pm$ 0.3       12.2 $\pm$ 0.4       0.001         Potassium (mmol/l)       4.0 $\pm$ 0.1       4.2 $\pm$ 0.1       0.300         C-reactive protein (mg/dl)       15.1 $\pm$ 3.9       49.9 $\pm$ 12.1       0.003         Troponin I (µg/l)       0.3 $\pm$ 0.1       0.4 $\pm$ 0.1       0.549         Medication at discharge, n (%)       34       (S5)       21       (T5)       0.302         Statin       23       (58)       14       (50)       0.541         Amiodarone       24       (60)       18       (64)       0.720         Aldosterone receptor antagonist       12       (31)       4       (13)       0.089         Diuretics       23       (59)       20       (67)       0.513         ECG data (mean $\pm$ SEM)       226 $\pm$ 16       204 $\pm$ 15       0.376         QRS       128 $\pm$ 21       127 $\pm$ 16       0.957         QT       450 $\pm$ 18       423 $\pm$ 23       0.378	VT ablation	9	(23)	8	(27)	0.687
Creatinine (mg/dl) $1.06 \pm 0.003$ $1.49 \pm 0.007$ $0.001$ GFR (ml/min/1.73 m <sup>2</sup> ) $60.6 \pm 0.53$ $43 \pm 3.73$ $0.001$ Hemoglobin (g/dl) $13.8 \pm 0.3$ $12.2 \pm 0.4$ $0.001$ Potassium (mmol/l) $4.0 \pm 0.1$ $4.2 \pm 0.1$ $0.003$ C-reactive protein (mg/dl) $15.1 \pm 3.9$ $49.9 \pm 12.1$ $0.003$ Troponin I (µg/l) $0.3 \pm 0.1$ $0.4 \pm 0.1$ $0.549$ Medication at discharge, $n$ (%) $34$ (85) $21$ (75) $0.302$ Statin $23$ (58) $14$ (50) $0.541$ Amiodarone $24$ (60) $18$ (64) $0.720$ Aldosterone receptor antagonist $12$ (31) $4$ (13) $0.089$ Diuretics $23$ (59) $20$ (67) $0.513$ ECG data (mean $\pm$ SEM) $26 \pm 16$ $204 \pm 15$ $0.376$ QRS $128 \pm 21$ $127 \pm 16$ $0.957$ OT $450 \pm 18$ $423 \pm 23$ $0.378$	Laboratory data (mean ±SEM)					
GFR (ml/min/1.73 m²) $60.6 \pm 0.53$ $43 \pm 3.73$ $0.001$ Hemoglobin (g/dl) $13.8 \pm 0.3$ $12.2 \pm 0.4$ $0.001$ Potassium (mmol/l) $4.0 \pm 0.1$ $4.2 \pm 0.1$ $0.300$ C-reactive protein (mg/dl) $15.1 \pm 3.9$ $49.9 \pm 12.1$ $0.003$ Troponin I (µg/l) $0.3 \pm 0.1$ $0.4 \pm 0.1$ $0.549$ Medication at discharge, $n$ (%) $34$ (85) $21$ (75) $0.302$ ACE inhibitor/ARB $34$ (85) $21$ (75) $0.302$ Statin $23$ (58) $14$ (50) $0.541$ Amiodarone $24$ (60) $18$ (64) $0.720$ Aldosterone receptor antagonist $12$ (31) $4$ (13) $0.089$ Diuretics $23$ (59) $20$ (67) $0.513$ ECG data (mean $\pm$ SEM) $226 \pm 16$ $204 \pm 15$ $0.376$ QRS $128 \pm 21$ $127 \pm 16$ $0.957$ QT $450 \pm 18$ $423 \pm 23$ $0.378$	Creatinine (mg/dl)	$1.06\pm0.003$		$1.49\pm0.007$		0.001
Hemoglobin (g/dl) $13.8 \pm 0.3$ $12.2 \pm 0.4$ $0.001$ Potassium (mmol/l) $4.0 \pm 0.1$ $4.2 \pm 0.1$ $0.300$ C-reactive protein (mg/dl) $15.1 \pm 3.9$ $49.9 \pm 12.1$ $0.003$ Troponin I (µg/l) $0.3 \pm 0.1$ $0.4 \pm 0.1$ $0.549$ Medication at discharge, $n$ (%) $38$ (95) $30$ (100) $0.230$ ACE inhibitor/ARB $34$ (85) $21$ (75) $0.302$ Statin $23$ (58) $14$ (50) $0.541$ Amiodarone $24$ (60) $18$ (64) $0.720$ Aldosterone receptor antagonist $12$ (31) $4$ (13) $0.089$ Diuretics $23$ (59) $20$ (67) $0.513$ ECG data (mean $\pm$ SEM) $226 \pm 16$ $204 \pm 15$ $0.376$ QRS $128 \pm 21$ $127 \pm 16$ $0.957$ QT $450 \pm 18$ $423 \pm 23$ $0.378$	GFR (ml/min/1.73 m <sup>2</sup> )	$60.6 \pm 0.53$		$43\pm3.73$		0.001
Potassiun (nmol/l) $4.0 \pm 0.1$ $4.2 \pm 0.1$ $0.300$ C-reactive protein (mg/dl) $15.1 \pm 3.9$ $49.9 \pm 12.1$ $0.003$ Troponin I (µg/l) $0.3 \pm 0.1$ $0.4 \pm 0.1$ $0.549$ Medication at discharge, $n$ (%) $38$ (95) $30$ (100) $0.230$ ACE inhibitor/ARB $34$ (85) $21$ (75) $0.302$ Statin $23$ (58) $14$ (50) $0.541$ Amiodarone $24$ (60) $18$ (64) $0.720$ Aldosterone receptor antagonist $12$ $(31)$ $4$ $(13)$ $0.089$ Diuretics $23$ (59) $20$ (67) $0.513$ ECG data (mean $\pm$ SEM) $226 \pm 16$ $204 \pm 15$ $0.376$ QRS $128 \pm 21$ $127 \pm 16$ $0.957$ OT $450 \pm 18$ $423 \pm 23$ $0.378$	Hemoglobin (g/dl)	$13.8\pm0.3$		$12.2 \pm 0.4$		0.001
C-reactive protein (mg/dl) $15.1 \pm 3.9$ $49.9 \pm 12.1$ $0.003$ Troponin I (µg/l) $0.3 \pm 0.1$ $0.4 \pm 0.1$ $0.549$ Medication at discharge, n (%) $38$ (95) $30$ (100) $0.230$ ACE inhibitor/ARB $34$ (85) $21$ (75) $0.302$ Statin $23$ (58) $14$ (50) $0.541$ Amiodarone $24$ (60) $18$ (64) $0.720$ Aldosterone receptor antagonist $12$ (31) $4$ (13) $0.089$ Diuretics $23$ (59) $20$ (67) $0.513$ ECG data (mean $\pm$ SEM) $226 \pm 16$ $204 \pm 15$ $0.376$ QRS $128 \pm 21$ $127 \pm 16$ $0.957$ QT $450 \pm 18$ $423 \pm 23$ $0.378$	Potassium (mmol/l)	$4.0 \pm 0.1$		$4.2 \pm 0.1$		0.300
Troponin I (µg/l) $0.3 \pm 0.1$ $0.4 \pm 0.1$ $0.549$ Medication at discharge, $n$ (%)38(95)30(100)0.230Beta-blocker38(95)30(100)0.230ACE inhibitor/ARB34(85)21(75)0.302Statin23(58)14(50)0.541Amiodarone24(60)18(64)0.720Aldosterone receptor antagonist12(31)4(13)0.089Diuretics23(59)20(67)0.513ECG data (mean $\pm$ SEM)226 $\pm 16$ 204 $\pm 15$ 0.376QRS128 $\pm 21$ 127 $\pm 16$ 0.957OT450 $\pm 18$ 423 $\pm 23$ 0.378	C-reactive protein (mg/dl)	$15.1 \pm 3.9$		$49.9 \pm 12.1$		0.003
Medication at discharge, $n$ (%)Beta-blocker38(95)30(100)0.230ACE inhibitor/ARB34(85)21(75)0.302Statin23(58)14(50)0.541Amiodarone24(60)18(64)0.720Aldosterone receptor antagonist12(31)4(13)0.089Diuretics23(59)20(67)0.513ECG data (mean $\pm$ SEM)226 $\pm$ 16204 $\pm$ 150.376QRS128 $\pm$ 21127 $\pm$ 160.957OT450 $\pm$ 18423 $\pm$ 230.378	Troponin I (µg/l)	$0.3\pm0.1$		$0.4\pm0.1$		0.549
Beta-blocker38(95)30(100)0.230ACE inhibitor/ARB34(85)21(75)0.302Statin23(58)14(50)0.541Amiodarone24(60)18(64)0.720Aldosterone receptor antagonist12(31)4(13)0.089Diuretics23(59)20(67)0.513ECG data (mean $\pm$ SEM)226 $\pm$ 16204 $\pm$ 150.376QRS128 $\pm$ 21127 $\pm$ 160.957OT450 $\pm$ 18423 $\pm$ 230.378	Medication at discharge, $n$ (%)					
ACE inhibitor/ARB34(85)21(75)0.302Statin23(58)14(50)0.541Amiodarone24(60)18(64)0.720Aldosterone receptor antagonist12(31)4(13)0.089Diuretics23(59)20(67)0.513ECG data (mean $\pm$ SEM)226 $\pm$ 16204 $\pm$ 150.376QRS128 $\pm$ 21127 $\pm$ 160.957OT450 $\pm$ 18423 $\pm$ 230.378	Beta-blocker	38	(95)	30	(100)	0.230
Statin23(58)14(50)0.541Amiodarone24(60)18(64)0.720Aldosterone receptor antagonist12(31)4(13)0.089Diuretics23(59)20(67)0.513ECG data (mean $\pm$ SEM)226 $\pm$ 16204 $\pm$ 150.376QRS128 $\pm$ 21127 $\pm$ 160.957OT450 $\pm$ 18423 $\pm$ 230.378	ACE inhibitor/ARB	34	(85)	21	(75)	0.302
Amiodarone24(60)18(64)0.720Aldosterone receptor antagonist12(31)4(13)0.089Diuretics23(59)20(67)0.513ECG data (mean $\pm$ SEM)PQ226 $\pm$ 16204 $\pm$ 150.376QRS128 $\pm$ 21127 $\pm$ 160.957OT450 $\pm$ 18423 $\pm$ 230.378	Statin	23	(58)	14	(50)	0.541
Aldosterone receptor antagonist12 $(31)$ 4 $(13)$ $0.089$ Diuretics23 $(59)$ 20 $(67)$ $0.513$ ECG data (mean $\pm$ SEM)226 $\pm 16$ $204 \pm 15$ $0.376$ QRS128 $\pm 21$ 127 $\pm 16$ $0.957$ OT450 $\pm 18$ 423 $\pm 23$ $0.378$	Amiodarone	24	(60)	18	(64)	0.720
Diuretics23(59)20(67)0.513ECG data (mean $\pm$ SEM)226 $\pm$ 16204 $\pm$ 150.376QRS128 $\pm$ 21127 $\pm$ 160.957OT450 $\pm$ 18423 $\pm$ 230.378	Aldosterone receptor antagonist	12	(31)	4	(13)	0.089
ECG data (mean $\pm$ SEM)226 $\pm 16$ 204 $\pm 15$ 0.376QRS128 $\pm 21$ 127 $\pm 16$ 0.957OT450 $\pm 18$ 423 $\pm 23$ 0.378	Diuretics	23	(59)	20	(67)	0.513
PQ $226 \pm 16$ $204 \pm 15$ $0.376$ QRS $128 \pm 21$ $127 \pm 16$ $0.957$ OT $450 \pm 18$ $423 \pm 23$ $0.378$	ECG data (mean $\pm$ SEM)					
QRS $128 \pm 21$ $127 \pm 16$ $0.957$ OT $450 \pm 18$ $423 \pm 23$ $0.378$	PQ	$226\pm16$		$204\pm15$		0.376
OT $450 \pm 18$ $423 \pm 23$ 0.378	QRS	$128 \pm 21$		$127\pm16$		0.957
	QT	$450\pm18$		$423\pm23$		0.378

🖄 Springer

#### Table 1 (continued)

Characteristic	Non-CKD (n	Non-CKD ( <i>n</i> = 40; 57%)		CKD $(n = 30; 43\%)$				
LVEF, n (%)								
≥55%	7	(19)	0	(0)	0.015			
54-45	4	(11)	3	(11)				
44–35%	6	(17)	1	(3)				
< 35%	19	(53)	24	(86)				
Type of ICD, $n$ (%)								
ICD	36	(90)	26	(87)	0.233			
CRT-D	2	(5)	4	(13)				
s-ICD	2	(5)	0	(0)				
ICD indication, $n$ (%)								
Primary prevention	15	(38)	11	(38)	0.971			
Secondary prevention	25	(62)	18	(62)				
ICD programming, bpm, median (IQR)	)							
VT detection threshold	171 (158–17	171 (158–176)		167 (154–171)				
VF detection threshold	214 (214–22	21)	214 (214–2	222)	0.761			

ACE angiotensin-converting enzyme, AKI acute kidney injury ARB angiotensin receptor blocker, COPD chronic obstructive pulmonary disease, CKD chronic kidney disease, CPR cardiopulmonary resuscitation, CRT-D cardiac resynchronization therapy defibrillator, ECG electrocardiogram, ES electrical storming, GFR glomerular filtration rate, ICD implantable cardioverter–defibrillator, IQR interquartile range, LVEF left ventricular ejection fraction, SEM standard error of measurement, VF ventricular fibrillation, VT ventricular tachycardia

Italic indicates the significance level p < 0.05

# **4** Discussion

Table 2 Primary and secondary

endpoints

The present study evaluates the prognostic impact of CKD in consecutive high-risk patients presenting with ES on admission. This data suggests that ES patients reveal a higher long-term mortality at 3 years in the presence of CKD. Respectively, increasing rates of the secondary endpoint MACE were seen in CKD patients. In contrast in-hospital mortality rates, risk of first cardiac rehospitalization, and ES-R were not affected by CKD. Prognostic differences were demonstrated even within the multivariable Cox regression model, where both CKD and LVEF < 35% were still associated with long-term mortality at 3 years. This study identifies the presence of CKD as a robust predictor of adverse prognosis in ES patients.

CKD is an independent predictor of cardiovascular morbidity and mortality [17, 18]. The most common cause of death in hemodialysis patients is sudden cardiac death (SCD) [10]. Although dialysis patients show the highest risk of cardiovascular events, even mild CKD stages are associated with ventricular tachyarrhythmias and SCD [18].

Potential risk factors and the resulting preventive therapeutic options of patients with ventricular tachyarrhythmias have been discussed continuously within the past years [12, 19]. According to international guideline recommendations, the implantation of an ICD is strongly recommended in patients with systolic heart failure defined as LVEF < 35% irrespective of the underlying cardiac disease [20]. However, especially in the presence of ischemic cardiomyopathy, as defined by a history of relevant CAD or prior myocardial infarction, ICD

Characteristic	Non-CKD ( <i>n</i> = 40; 57%)		CKD ( <i>n</i> = 30; 43%)		p value	
Primary endpoint, n (%)						
All-cause mortality at 3 years	8	(20)	19	(63)	0.001	
Secondary endpoints, n (%)						
In-hospital mortality	0	(0)	2	(7)	0.180	
First cardiac rehospitalization	18	(45)	13	(43)	0.889	
MACE	12	(30)	17	(57)	0.025	
ES recurrence	8	(20)	9	(30)	0.334	

ES electrical storm, MACE major adverse cardiac events

Italic indicates the significance level p < 0.05

Fig 1 Prognostic impact of CKD on long-term all-cause mortality (left panel) and rehospitalization (right panel) in patients presenting with ES



implantation was shown to be associated with reduced allcause mortality [19]. Although ICD implantation is recommended for patients with systolic heart failure and nonischemic (dilatative) cardiomyopathy (DCM) [20]. the DANISH trial recently reported that primary preventive ICD implantation in patients with non-ischemic cardiomyopathy was not associated with improved long-term prognosis (i.e., death from any cause and cardiovascular death). However, the risk of sudden cardiac death was significantly reduced in the ICD group [12]. We recently demonstrated that neither the presence of ischemic cardiomyopathy compared to nonischemic cardiomyopathy revealed any differences in prognostic outcomes in ICD recipients presenting with ventricular tachyarrhythmias at index. However, patients with nonischemic cardiomyopathy showed higher rates of recurrent ventricular tachyarrhythmias at 1 year [21].

Focusing on the prognostic impact of CKD in patients with ventricular tachyarrhythmias—representing a not well-studied risk factor in this subset of patients—it was demonstrated that CKD patients were significantly associated with increased long-term mortality at 2 years, cardiac death, and in-hospital death, which is also reflected within the corresponding RACE-IT CKD risk score [22]. Even in ICD recipients, only CKD was still associated with increased long-term mortality, recurrent ventricular tachyarrhythmias, and appropriate device therapies at 5 years [23].

In clear contrast, data in ES patients with CKD is rare. Potential risk factors for ES are widely discussed, and the specific causative pathology for the development of ES is not yet fully understood, not even in higher-risk patients with relevant comorbidities, such as CKD and heart failure [3, 5]. As demonstrated by the present analysis, the presence of both CKD and LVEF < 35% was shown to be significantly associated with increased all-cause mortality. Both comorbidities may reflect the presence of the cardiorenal syndrome, which is defined as "disorders of the heart and kidneys, whereby acute or chronic dysfunction in one organ may induce acute or chronic dysfunction of the other" [8, 24]. The cardiorenal syndrome is categorized into 5 subtypes based on the organ presumed to be the primary trigger [8, 24]. Although this definition is of clinical importance, it reveals less information about the underlying pathophysiological pathways. Interstitial fibrosis in the heart, vessel wall structure, and kidney has been identified as responsible pathogenetic factors in most types of the cardiorenal syndrome [25]. In the present analysis, CKD patients with ES were older and had a numerically increased cardiovascular risk profile. Aging and risk factors, such as arterial hypertension, dyslipidemia, and diabetes mellitus,





 Table 3
 Multivariable Cox regression model to evaluate prognostic factors associated with long-term mortality at 3 years

Variable	HR	95% CI	p value
Age	1.023	0.978-1.071	0.316
Diabetes mellitus	0.896	0.385-2.087	0.799
Chronic kidney disease <sup>a</sup>	2.397	1.012-5.697	0.047
LVEF < 35%	9.015	1.141-71.126	0.037
Atrial fibrillation	1.338	0.617-2.905	0.461

CI confidence interval, HR, hazard ratio, LVEF left ventricular ejection fraction

<sup>a</sup> Defined as creatinine > 1.2 mg/dl

Italic indicates the significance level p < 0.05

may lead to sympathetic neurohumoral activation, chronic inflammation, and oxidative stress related to endothelial dysfunction. In turn, these conditions may alleviate, leading to heart and kidney failure due to the increasing amount of interstitial fibrosis and activation of the renin–angiotensin–aldosterone system (RAAS). Myocardial fibrosis attenuates cardiomyocyte coupling and thereby may enhance arrhythmogenicity [10]. Therefore, interstitial fibrosis may reflect the main causative pathology in cardiorenal syndrome [24, 25].

Furthermore, other explanations for the increased cardiovascular mortality in CKD patients do exist [10]. Myocardial ischemia related to coronary artery disease represents major comorbidity in CKD patients [10]. It has recently been demonstrated that ventricular tachyarrhythmias and SCD after myocardial infarction are more common in the presence of CKD [26]. In the present study, patients with CKD showed significantly higher rates of ischemic cardiomyopathy, which might further confirm these findings and explain the increased long-term mortality and higher rates of MACE in the present study evaluating patients with ES.

The present study demonstrated that CKD patients presenting with ES were associated with increased rates of long-term mortality and MACE compared to non-CKD patients. This

 Table 4
 Multivariable Cox regression model to evaluate prognostic factors influencing the secondary endpoint MACE

Variable	HR	95% CI	p value
Age	1.013	0.975-1.052	0.496
Diabetes mellitus	1.010	0.451-2.263	0.981
Chronic kidney disease <sup>a</sup>	2.520	1.109-5.727	0.027
LVEF < 35%	2.192	0.679-7.073	0.189
Atrial fibrillation	1.363	0.650-2.859	0.412

CI confidence interval, HR hazard ratio, LVEF left ventricular ejection fraction

<sup>a</sup> Defined as creatinine > 1.2 mg/dl

Italic indicates the significance level p < 0.05

negative prognostic impact of CKD in ES patients may be related to the cardiorenal syndrome due to myocardial and renal fibrosis, increased cardiovascular risk profile, and ischemic cardiomyopathy, which may explain the adverse prognostic impact of CKD in ES patients. However, further–at bestrandomized controlled trials are needed to investigate the prognostic impact, its pathophysiological pathways, and potential therapeutic options in high-risk ES patients with CKD. The supposed benefit of excluding CKD patients from RCT, especially in high-risk patients with ES, needs to be further debated [1, 8].

## **5 Study limitations**

The present study is based on rather small sample size, with only 70 patients included in a retrospective and observational single-center registry. Rehospitalization rates were only documented within our own institution. Patients with prolonged hemodynamic instability and lethal outcome before admission and those not surviving out-of-hospital CPR without transfer to the heart center were not included in this study. Ablation rates among ES patients were low, possibly preventing showing a beneficial effect of ablation. Future prospective randomized controlled trials are needed to further clarify the prognostic impact of VT ablation in ES patients.

## 6 Conclusion

In patients with ES, the presence of CKD is significantly associated with increased rates of long-term mortality at 3 years and MACE compared with non-CKD patients.

Acknowledgements Open Access funding enabled and organized by Projekt DEAL.

#### Compliance with ethical standards

**Conflict of interest** The authors declare that they have no conflict of interest.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

## References

- Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death–executive summary: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Eur Heart J. 2006;27(17):2099–140.
- 2. Israel CW, Barold SS. Electrical storm in patients with an implanted defibrillator: a matter of definition. Ann Noninvasive Electrocardiol. 2007;12(4):375–82.
- Israel CW, Manegold JC. Electrical storm: definition, prevalence, causes and prognostic implications. Herzschrittmacherther Elektrophysiol. 2014;25(2):59–65.
- 4. Hendriks AA, Szili-Torok T. Editor's Choice-The treatment of electrical storm: an educational review. Eur Heart J Acute Cardiovasc Care. 2018;7(5):478–83.
- Gadula-Gacek E, Tajstra M, Gasior M. Electrical storm still an extremely poor prognosis. Do these acute states of life-threatening arrhythmias require a multidirectional approach from the start? Postepy Kardiol Interwencyjnej. 2019;15(1):1–12.
- Linz D, Hohl M, Elliott AD, Lau DH, Mahfoud F, Esler MD, et al. Modulation of renal sympathetic innervation: recent insights beyond blood pressure control. Clin Auton Res. 2018;28(4):375–84.
- Brigadeau F, Kouakam C, Klug D, Marquie C, Duhamel A, Mizon-Gerard F, et al. Clinical predictors and prognostic significance of electrical storm in patients with implantable cardioverter defibrillators. Eur Heart J. 2006;27(6):700–7.
- Zannad F, Rossignol P. Cardiovascular outcome trials in patients with advanced kidney disease: time for action. Circulation. 2017;135(19):1769–71.
- Rossignol P, Agarwal R, Canaud B, Charney A, Chatellier G, Craig JC, et al. Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints. Eur Heart J. 2019;40(11):880–6.
- Boriani G, Savelieva I, Dan GA, Deharo JC, Ferro C, Israel CW, et al. Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace. 2015;17(8): 1169–96.
- 11. Herring N. The kidney-heart connection during electrical storm: from bedside back to bench. Exp Physiol. 2014;99(11):1451–2.
- Kober L, Thune JJ, Nielsen JC, Haarbo J, Videbaek L, Korup E, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375(13):1221–30.

- Andrassy KM. Comments on 'KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease'. Kidney Int. 2013;84(3):622–3.
- Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Kardiol Pol. 2018;76(2):229–313.
- Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction (2018). Kardiol Pol. 2018;76(10):1383–415.
- Kip KE, Hollabaugh K, Marroquin OC, Williams DO. The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention. J Am Coll Cardiol. 2008;51(7):701–7.
- Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305.
- Chronic Kidney Disease Prognosis C, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073–81.
- Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877–83.
- Jung W, Andresen D, Block M, Bocker D, Hohnloser SH, Kuck KH, et al. Guidelines for the implantation of defibrillators. Clin Res Cardiol. 2006;95(12):696–708.
- Rusnak J, Behnes M, Schupp T, Weiss C, Nienaber C, Lang S, et al. Comparable survival in ischemic and nonischemic cardiomyopathy secondary to ventricular tachyarrhythmias and aborted cardiac arrest. Coron Artery Dis. 2019;30(4):303–11.
- Weidner K, Behnes M, Schupp T, Rusnak J, Reiser L, Taton G, et al. Prognostic impact of chronic kidney disease and renal replacement therapy in ventricular tachyarrhythmias and aborted cardiac arrest. Clin Res Cardiol. 2019;108(6):669–82.
- Weidner K, Behnes M, Weiss C, Nienaber C, Reiser L, Bollow A, et al. Impact of chronic kidney disease on recurrent ventricular tachyarrhythmias in ICD recipients. Heart Vessels. 2019;34(11): 1811–22.
- Ronco C, Ronco F. Cardio-renal syndromes: a systematic approach for consensus definition and classification. Heart Fail Rev. 2012;17(2):151–60.
- 25. Zannad F. Response to comment on the editorial by Turner et al. on assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion by Zannad et al. Eur Heart J Cardiovasc Pharmacother. 2017;3(3):131.
- Poulikakos D, Banerjee D, Malik M. Risk of sudden cardiac death in chronic kidney disease. J Cardiovasc Electrophysiol. 2014;25(2): 222–31.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.